ArticleInternational journal of molecular medicine2026
Novel Hsp90 inhibitor JD‑02 inhibits HSV‑1 infection via the Raf/MEK/ERK signaling pathway.
Article in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MEK/ERK-Mediated Transcriptional Repression of Metabolic Genes Confers Host Defense AgainstMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus type 1 (HSV‑1) is a neurotropic pathogen with an extremely high infection rate. The excessive use of acyclovir (ACV) and nucleoside analogs has resulted in the emergence of drug‑resistant HSV‑1 strains, thereby underscoring the need for the development of novel therapeutic agents against HSV‑1. The present study sought to evaluate the efficacy and elucidate the mechanism of action of the novel Hsp90 inhibitor, JD‑02, in the context of HSV‑1 infection, as well as to assess its potential as an anti‑HSV‑1 therapeutic agent. The results of the present study demonstrated that JD‑02 exhibits lower cytotoxicity relative to the conventional Hsp90 inhibitor, AT533, and effectively inhibits infection by both standard and ACV‑resistant HSV‑1 strains
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.